中药注射剂联合CF化疗方案治疗乳腺癌有效性及安全性的网状Meta分析和试验序贯分析

doi:10.3969/j.issn.1007-9572.2016.27.014

摘要/Abstract

摘要： 目的　探讨中药注射剂联合CF化疗方案治疗乳腺癌的有效性和安全性。方法　2014年10月，计算机检索中国知网（CNKI）、中国生物医学文献数据库（CBM）、万方数据知识服务平台、维普网、ISI Web of Knowledge、EMBase、PubMed和Cochrane Library，纳入中药注射剂联合CF化疗方案对比CF化疗方案治疗乳腺癌的随机对照试验（RCTs），由2名评价员独立提取数据和质量评价，采用Stata 12.0、WinBUGS 1.4统计学软件和试验序贯分析统计学软件分别执行网状Meta分析和试验序贯分析。结果　最终纳入26篇RCTs，包含1 884例患者，共涉及6种中药注射剂（复方苦参注射液、康艾注射液、康莱特注射液、艾迪注射液、华蟾素注射液、参芪扶正注射液）。网状Meta分析结果和概率排序结果显示复方苦参、康莱特联合CF化疗方案在提高有效性指标和改善患者生活质量方面优于其他方案，然而，在降低恶心呕吐（Ⅲ～Ⅳ级）和白细胞计数减少（Ⅲ～Ⅳ级）发生率方面参芪扶正、艾迪联合CF化疗方案效果更好。结论　目前尚无有力证据显示在提高乳腺癌治疗有效性指标、生活质量，降低患者恶心呕吐和白细胞计数减少等方面的最佳中药注射剂联合CF化疗方案，临床实践中应当根据患者的病情合理选择用药。

关键词: 乳腺肿瘤, 中草药, 注射剂, 抗肿瘤联合化疗方案, Meta分析

Abstract: Objective　To assess the efficacy and safety of traditional Chinese medicine injection（TCMI） combined with CF chemotherapy（TCMI + CF） for breast cancer.Methods　In October 2014,a computer-based retrieval was performed including CNKI,CBM,Wangfang Data knowledge Service Platform,VIP database,ISI Web of Knowledge,EMBase,PubMed and Cochrane Library,to include RCTs that comparing TCMI + CF and pure CF chemotherapy for breast cancer.Two evaluators conducted data extraction and quality evaluation separately.Stata 12.0,WinBUGS 1.4 and TSA were used to conduct network Meta analysis and trial sequential analysis.Results　We included 26 RCTs involving 1 884 patients and 6 kinds of TCMI （Fufang Kushen injection，Kang’ai injection,Kanglaite injection，Aidi injection,Huachansu injection,Shenqifuzheng injection）.The results of network Meta-analysis showed that Fufang Kushen and Kanglaite combined with CF chemotherapy were better than other injections in the improvement of overall effectiveness index and quality of life.However,Shenqifuzheng and Aidi combined with CF chemotherapy were better in reducing nausea and vomiting （grade Ⅲ-Ⅳ） and decrease in white blood cell count（grade Ⅲ-Ⅳ）.Conclusion　At present,there is still no strong evident that TCMI + CF is the best therapy in effective rate,improving quality of life,reducing nausea and vomiting,and inhibiting decrease in white blood cell count.Therefore,rational choice of drug should be made for patients in clinical practice.

Key words: Breast neoplasms, Drugs,Chinese herbal, Injectio, Antineoplastic combined chemotherapy protocols, Meta-analysis

田金徽, 葛龙, 娄丽丽, 谢吻, 甘雨虹, 裴改琴, 王权, 刘锐锋, 张秋宁, 王小虎, 张红. 中药注射剂联合CF化疗方案治疗乳腺癌有效性及安全性的网状Meta分析和试验序贯分析[J]. 中国全科医学, 2016, 19(27): 3326-3335.

TIAN Jin-hui, GE Long, LOU Li-li, XIE Wen, GAN Yu-hong, PEI Gai-qin, WANG Quan, LIU Rui-feng, ZHANG Qiu-ning, WANG Xiao-hu, ZHANG Hong. . Effectiveness and Safety of Traditional Chinese Medicine Injection Combined with CF Chemotherapy Regimen in the Treatment of Breast Cancer:Network Meta-analysis and Trial Sequential Analysis[J]. Chinese General Practice, 2016, 19(27): 3326-3335.

参考文献

［1］SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2015 ［J］.CA Cancer J Clin,2015,65（1）:5-29. ［2］International Agency for Research on Cancer.GLOBOCAN 2012：Estimated Cancer Incidence,Mortality and Prevalence Worldwide in 2012［R/OL］.［2014-10-20］.http：//globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. ［3］吴一龙.恶性肿瘤多学科综合治疗的困境［J］.循证医学,2008,8（1）:1-2. WU Y L.Challenge of malignant neoplasm synthetic therapy ［J］.Journal of Evidence-Based Medicine,2008,8（1）:1-2. ［4］CALDWELL D M,ADES A E,HIGGINS J P.Simultaneous comparison of multiple treatments:combining direct and indirect evidence［J］.BMJ,2005,331（7521）:897-900. ［5］孙飞.中医药联合化疗治疗乳腺癌临床疗效的Meta分析［D］.南京：南京中医药大学,2013. SUN F.Meta analysis of clinical effects from the traditional Chinese medicine combined with chemotherapy for breast cancer ［D］.Nanjing：Nanjing University of Chinese Medicine,2013. ［6］刘磊,邬文洁,周仲浩，等.复方苦参注射液联合化疗治疗乳腺癌近期疗效及生存质量的Meta分析［J］.浙江中医杂志,2012,47（4）:297-299. ［7］梁芳,张青松,张丽娟,等.参芪扶正注射液联合化疗治疗乳腺癌的Meta分析［J］.中国实用医药,2014,9（3）:175-176. ［8］刘潇,吴斌,徐珽.康艾注射液辅助治疗乳腺癌的疗效和安全性的Meta分析［J］.中国药房,2013,24（32）:3047-3050. LIU X,WU B,XU T.Meta-analysis of therapeutic efficacy and safety of kangai injection in the adjunctive treatment of breast cancer ［J］.China Pharmacy,2013,24（32）:3047-3050. ［9］刘爱萍,李伦,赵晔,等.当归多糖抗辐射效果的网状Meta分析［J］.中国药物评价,2014,31（2）:107-112. LIU A P,LI L,ZHAO Y,et al.Network meta-analysis of angelica polysaccharides for radioactivity protection ［J］.Chinese Journal of Drug Evaluation,2014,31（2）:107-112. ［10］王权,田金徽,李伦,等.试验序贯分析简介［J］.中国循证医学杂志,2013,13（10）:1265-1268. WANG Q,TIAN J H,LI L,et al.Brief introduction of trial sequential analysis ［J］.Chinese Journal of Evidence-Based Medicine,2013,13（10）:1265-1268. ［11］HIGGINS J,GREEN S E.Cochrane handbook for systematic reviews of interventions version 5.1.0.The cochrane collaboration,2011［R/OL］.［2014-10-20］.http://www.cochrane-handbook.org. ［12］王雷,刘洁.CTF方案联合岩舒注射液在乳腺癌新辅助化疗中的临床观察［J］.中国医药导报,2007,4（24）:55,97. ［13］孙学民.复方苦参注射液对乳腺癌术后化疗患者免疫功能的影响［J］.同济大学学报（医学版）,2009,30（1）:117-120. SUN X M.Effects of Matrine on immune functions in patients with breast carcinoma undergoing chemotherapy after surgery operation ［J］.Journal of Tongji University （Medical Science）,2009,30（1）:117-120. ［14］任建鸿,王红,刘丽梅,等.复方苦参注射液联合CAF方案治疗早期乳腺癌改良根治术后患者123例的临床观察［J］.中国医院用药评价与分析,2010,10（8）:736-739. REN J H,WANG H,LIU L M,et al.Clinical observation on matrine injection combined with “CAF” chemotherapy for one hundred and twenty-three patients with early breast carcinoma underwent modified radical mastectomy ［J］.Evaluation and Analysis of Drug-use in Hospital of China,2010,10（8）:736-739. ［15］朱琨,李康,党诚学,等.参芪扶正注射液对乳腺癌术后行CEF方案化疗患者免疫功能的影响［J］.现代肿瘤医学,2008,16（10）:1712-1714. ZHU K,LI K,DANG C X，et al.Effects of Shenqifuzheng injection on immune functions in patients with breast carcinoma undergoing CEF regimen after surgery operation ［J］.Journal of Modern Oncology,2008,16（10）:1712-1714. ［16］徐平,戎煜明,龚亚斌,等.康艾注射液对乳腺癌患者CEF方案化疗毒性反应影响的临床研究［J］.现代中医药,2010,30（1）:3-4. XU P,RONG Y M,GONG Y B,et al.Kang’ai injection:clinical study of its effect on toxic reaction of CEF chemotherapy on breast cancer patients ［J］.Modern Traditional Chinese Medicine,2010,30（1）:3-4. ［17］邓安.康艾注射液联合化疗治疗乳腺癌的疗效分析［J］.中国保健营养:中旬刊,2012,23（11）:10. ［18］吴薏婷,吴锦燕.康艾注射液联合化疗治疗晚期乳腺癌30例疗效观察［J］.新中医,2011,43（6）:88-89. ［19］潘琦,何东初,丁晓娟.康艾注射液配合化疗治疗乳腺癌的临床观察［J］.湖北中医杂志,2008,30（10）:14-15. PAN Q,HE D C,DING X J.Clinical observation on treatment of breast cancer with Kang’ai injection combined with chemotherapy［J］.Hubei Journal of Traditional Chinese Medicine,2008,30（10）:14-15. ［20］吴峰.康艾注射液配合乳腺癌术后辅助化疗的临床疗效观察［J］.世界中西医结合杂志,2010,5（6）:522-524. WU F.Observation of the clinical observation of Kangai injection combined with accessory chemotherapy after breast cancer operation ［J］.World Journal of Interated Traditional and Western Medicine,2010,5（6）:522-524. ［21］王宇,王宽宇.康艾注射液治疗乳腺癌的临床疗效［J］.中国现代药物应用,2011,5（21）:59-60. ［22］祝超,孙银萍.乳腺癌术后应用康艾注射液联合化疗随机对照临床研究［J］.实用中医内科杂志,2012,26（9）:61-63. ZHU C,SUN Y P.Breast cancer surgery Kangai injection chemotherapy combined application of the clinical curative effect ［J］.Journal of Practical Traditional Chinese Internal Medicine,2012,26（9）:61-63. ［23］黄智芬,韦劲松,刘俊波,等.复方苦参注射液联合化疗治疗晚期乳腺癌患者对免疫功能的影响［C］//第三届国际中医、中西医结合肿瘤学术交流大会暨第十二届全国中西医结合肿瘤学术大会论文集,2010：670-672. ［24］甘霖霖,于镜泊,张海青,等.康莱特注射液在乳腺癌新辅助化疗中的作用［J］.肿瘤,2009,29（3）:283-285. GAN L L,YU J B,ZHANG H Q,et al.Role of Kanglaite injection of neoadjuvant chemotherapy of breast cancer ［J］.Tumor,2009,29（3）:283-285. ［25］谢小红,顾锡冬,赵虹.薏苡仁提取物联合新辅助化疗对局部晚期乳腺癌组织Survivin及Ki-67表达的影响［J］.浙江中医药大学学报,2014,38（6）:671-675. XIE X H,GU X D,ZHAO H.The expression of Ki-67 and survivin on focally advanced breast cancer after KLT combined neoadjuvant chemotherapy ［J］.Journal of Zhejiang Chinese Medical University,2014,38（6）:671-675. ［26］王梅,武力.艾迪注射液对乳腺癌患者血清VEGF水平的影响［J］.中国临床研究,2013,26（11）:1151-1152,1158. WANG M,WU L.Effect of Aidi injection on serum VEGF in patients with breast cancer ［J］.Chinese Journal of Clinical Research,2013,26（11）:1151-1152,1158. ［27］党相国,王琳.艾迪注射液联合CTF方案新辅助化疗对乳腺癌的疗效评价及血清sFas的影响［J］.世界中西医结合杂志,2010,5（1）:54-56. DANG X G,WANG L.Evaluation of efficacy on breast cancer treated by Aidi injection plus CTF program of neoadjuvant chemotherapy and the impacts on serum sFas ［J］.World Journal of Interated Traditional and Western Medicine,2010,5（1）:54-56. ［28］李湘奇,宫少波.艾迪注射液配合CEF方案化疗对乳腺癌的疗效分析［J］.中药药理与临床,2006,22（3）:176-177. ［29］叶鑫,邱代聪,代菊英,等.爱迪注射液联合CAF方案治疗晚期乳腺癌临床观察［J］.成都军区医院学报,2002,4（2）:11-12. YE X,QIU D C,DAI J Y,et al.Clinical observation of Aidi injection combined with CAF cancer for advanced breast cancer ［J］.Journal of Chengdu Military Hospital,2002,4（2）:11-12. ［30］任志国,张峰.高剂量艾迪注射联合化疗治疗乳腺癌60例疗效观察［J］.临沂医学专科学校学报,2005,27（5）:341-343. REN Z G,ZHANG F.High-doge Aidi injection and chemotherapy in treating 60 cases of mammary cancer ［J］.Journal of Linyi Medical College,2005,27（5）:341-343. ［31］韩永红,江学庆,杨桦,等.乳腺癌术后艾迪注射液联合CEF方案化疗的临床观察［J］.湖北中医杂志,2014,36（5）:7-8. HAN Y H,JIANG X Q,YANG H,et al.Clinical observation of Aidi inJection combined with CEF regimen chemotherapy in treatment of postoperative breast cancer ［J］.Hubei Journal of Traditional Chinese Medicine,2014,36（5）:7-8. ［32］潘领明.华蟾素联合化疗晚期乳腺癌160例分析［J］.中外医疗,2011,30（1）:59,61. ［33］宋文广,王瑞林,付占昭.华蟾素配合化疗治疗晚期乳腺癌临床观察［C］//第一届全国中西医结合乳腺疾病学术会议论文汇编,2002：149-151. ［34］陈芳,林红.参芪扶正注射液辅助乳癌化疗的疗效观察［J］.海峡药学,2007,19（12）:75-76. CHEN F,LIN H.Clinical observation of Shenqi Fuzheng injection in assist chemotherapy of breast cancer ［J］.Strait Pharmaceutical Journal,2007,19（12）:75-76. ［35］黄智芬,韦劲松,黎汉忠,等.参芪扶正注射液联合化疗治疗晚期乳腺癌30例临床观察［J］.中国中西医结合杂志,2008,28（2）:152-154. HUANG Z F,WEI J S,NI H Z,et al.Effect of Shenqi Fuzheng injection combined with chemotherapy on thirty patients with advanced breast cancer ［J］.Chinese Journal of Integraed Traditional and Western Medicine,2008,28（2）:152-154. ［36］代志军,王西京,康华峰,等.参芪扶正注射液在乳腺癌新辅助化疗中的疗效及不良反应的临床观察［J］.药物不良反应杂志,2007,9（1）:10-14. DAI Z J,WANG X J,KANG H F,et al.Clinical observation of efficacy and adverse reactions on Shenqifuzheng injection used in patients with breast cancer receiving neoadjuvant chemotherapy ［J］.Adverse Drug Reactions Journal,2007,9（1）:10-14. ［37］王道军.中西医药物联合治疗76例乳腺癌的疗效观察［J］.医学综述,2013,19（14）:2676-2678. WANG D J.Clinical observation of Chinese and western drugs for the treatment of 76 cases of breast cancer ［J］.Medical Recapitulate,2013,19（14）:2676-2678. ［38］NESCH E,REICHENBACH S,TRELLE S,et al.The importance of allocation concealment and patient blinding in osteoarthritis trials:a meta-epidemiologic study ［J］.Arthritis Rheum,2009,61（12）:1633-641.

[1]	张玲, 黄双英, 徐慧, 梅慧婷, 洪咏萍. 不同运动方式对老年人跌倒效能影响的网状Meta分析[J]. 中国全科医学, 2026, 29(06): 741-751.
[2]	赵雪姣, 李娟, 李雨洁, 卢婷, 先丽红, 颜欢. 中国脑卒中后认知障碍患病趋势及影响因素的Meta分析[J]. 中国全科医学, 2026, 29(03): 380-392.
[3]	周文超, 梁佳琪, 姚尚满, 薛朝, 刘龙, 郭相杰. 高血压与帕金森病的共享基因位点识别研究[J]. 中国全科医学, 2026, 29(02): 201-206.
[4]	向凤玲, 王远坤, 王小燕, 何圣洁, 干锦华. 中国儿童青少年高尿酸血症患病率的Meta分析[J]. 中国全科医学, 2025, 28(33): 4206-4213.
[5]	许佳兰, 阎红, 文君, 周紫彤, 王思宇. 老年癌症患者潜在不适当用药发生率的Meta分析[J]. 中国全科医学, 2025, 28(30): 3815-3822.
[6]	张天宇, 于海搏, 陈飞, 李新, 张佳佳, 詹晓凯, 申曼, 汤然, 范斯斌, 赵凤仪, 黄仲夏. POEMS综合征全身系统性治疗疗效和安全性的Meta分析[J]. 中国全科医学, 2025, 28(27): 3447-3455.
[7]	全家霖, 朱琳, 苏煜, 陈泽恺, 陈梓淇, 张卓凡. 运动方式对超重或肥胖儿童青少年执行功能改善效果的网状Meta分析[J]. 中国全科医学, 2025, 28(27): 3422-3431.
[8]	丁香, 刘健, 陈晓露, 张先恒. 中草药降低类风湿关节炎合并链球菌感染患者再入院的风险：一项匹配队列研究[J]. 中国全科医学, 2025, 28(24): 3005-3012.
[9]	刘银银, 隋鸿平, 李婷婷, 姜桐桐, 史铁英, 夏云龙. 乳腺癌治疗相关心脏毒性风险预测模型的研究进展[J]. 中国全科医学, 2025, 28(24): 3072-3078.
[10]	蒋世华, 朱政, 任盈盈, 朱垚磊, 王越, 高希彬. 中国儿童青少年近视患病率及影响因素的Meta分析[J]. 中国全科医学, 2025, 28(24): 3043-3052.
[11]	李浩, 李江涛, 刘丹, 王建军. 贝利尤单抗和阿尼鲁单抗及泰它西普治疗系统性红斑狼疮疗效和安全性的网状Meta分析[J]. 中国全科医学, 2025, 28(23): 2924-2933.
[12]	王笑林, 李秋月, 周彦君, 张金辉, 梁涛. 转移性结直肠癌患者呋喹替尼治疗相关心血管毒性发生率和风险的Meta分析[J]. 中国全科医学, 2025, 28(23): 2934-2940.
[13]	马盼盼, 王思静, 游娜, 丁大法, 鲁一兵. Danuglipron与Orforglipron治疗2型糖尿病疗效及安全性的Meta分析[J]. 中国全科医学, 2025, 28(21): 2679-2685.
[14]	胡婉琴, 余深艳, 曹学华, 向凤, 贾钰. 中国儿童性早熟影响因素的Meta分析[J]. 中国全科医学, 2025, 28(21): 2661-2671.
[15]	阿迪力·吐尔孙, 程刚. 非奈利酮治疗2型糖尿病肾病有效性和安全性的Meta分析[J]. 中国全科医学, 2025, 28(21): 2686-2691.